Transaction in Own Shares

Summary by AI ^BETAClose X

Hikma Pharmaceuticals Plc has repurchased 9,631,818 ordinary shares for a total cost of £130,317,376.42 as part of its $250 million share repurchase program. These repurchases occurred between June 15 and June 19, 2026, with the company intending to cancel the acquired shares. Following these transactions and the cancellation, Hikma will have 212,254,635 ordinary shares in issue, excluding treasury shares, resulting in a total of 212,254,635 voting rights. The company currently holds 12,833,233 ordinary shares in treasury.

Disclaimer*

Hikma Pharmaceuticals Plc

22 June 2026

HIKMA PHARMACEUTICALS PLC

TRANSACTIONS IN OWN SHARES

Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) (the ''Company'') announces that, during the period from 15 June 2026 to 19 June 2026 (inclusive) (the ''Disclosure Period''), it purchased the following number of its ordinary shares of 10 pence each through J.P. Morgan Securities plc as part of the second tranche (which commenced on 27 May 2026) of its $250 million share repurchase programme announced on 26 February 2026 (the ''Buyback Programme'').

Date within Disclosure Period	Trading Venue	Aggregate number of ordinary shares repurchased	Lowest price paid(pence)	Highest price paid (pence)	Volume-weighted average price (pence)
15 June 2026	XLON	102,806	1,472.0000	1,483.0000	1,475.8276
16 June 2026	BATE	38,351	1,462.0000	1,468.0000	1,464.8009
16 June 2026	XLON	132,649	1,460.0000	1,480.0000	1,467.6961
17 June 2026	AQXE	9,824	1,460.0000	1,463.0000	1,462.6856
17 June 2026	BATE	93,467	1,459.0000	1,468.0000	1,465.8490
17 June 2026	CHIX	16,219	1,459.0000	1,463.0000	1,462.6315
17 June 2026	TRQX	6,392	1,459.0000	1,463.0000	1,462.7829
17 June 2026	XLON	117,451	1,459.0000	1,477.0000	1,466.3286
18 June 2026	AQXE	11,353	1,449.0000	1,460.0000	1,455.2915
18 June 2026	BATE	100,215	1,446.0000	1,461.0000	1,454.0436
18 June 2026	CHIX	18,683	1,449.0000	1,460.0000	1,455.2551
18 June 2026	TRQX	7,521	1,451.0000	1,460.0000	1,455.6092
18 June 2026	XLON	128,723	1,446.0000	1,461.0000	1,453.8950
19 June 2026	AQXE	11,965	1,460.0000	1,474.0000	1,467.5480
19 June 2026	BATE	103,654	1,456.0000	1,474.0000	1,467.6821
19 June 2026	CHIX	19,700	1,454.0000	1,474.0000	1,467.4343
19 June 2026	TRQX	7,975	1,460.0000	1,474.0000	1,467.4392
19 June 2026	XLON	139,194	1,455.0000	1,476.0000	1,467.3681

The Company intends to cancel the repurchased shares.

Since the launch of the Buyback Programme on 26 February 2026, the Company has purchased a total of 9,631,818 ordinary shares at a total cost of £130,317,376.42.

The Company holds 12,833,233 of its ordinary shares in treasury.

Following the settlement of the above transactions and cancellation of the repurchased shares, the Company will have 212,254,635 ordinary shares in issue (excluding treasury shares) and the total number of voting rights in the Company will therefore be 212,254,635.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), a schedule of individual trades made by J.P. Morgan Securities plc as principal during the Disclosure Period pursuant to the Buyback Programme is available on the link below:

http://www.rns-pdf.londonstockexchange.com/rns/2519J_1-2026-6-22.pdf

Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal

EVP, Strategic Planning and Global Affairs +44 (0) 20 7399 2760 / +44 (0) 7776 477050

Guy Featherstone

Director, Investor Relations +44 (0) 20 3892 4389 / +44 (0) 7795 896738

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END